



Media Contact  
Dan McFadden  
[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)  
(425) 836-3103

## **OCULUS INNOVATIVE SCIENCES APPLIES FOR CE MARK APPROVAL FOR CALIFORNIA MANUFACTURING FACILITY**

### **Company also submits technical file for European CE Mark approval of “disruptive” Microcyn™ disinfectant.**

**PETALUMA, CA-- (Jan. 9, 2004)**— Oculus Innovative Sciences ([www.oculusis.com](http://www.oculusis.com)) management announced the company has submitted its technical file for CE Mark approval for use of Microcyn™ as a disinfectant in Europe while also successfully completing a site audit for the Petaluma, California manufacturing facility without indication of any non-conformities.

Microcyn is currently marketed in Mexico as both a disinfectant and antiseptic. It has proven safe, non-toxic, and non-flammable while it eradicates viruses, bacteria, spores and molds quickly and effectively. The approval by the Mexican Ministry of Health in July of 2003 allows for the use of Microcyn as a commercial disinfectant for hard surfaces and medical devices, as well as an antiseptic for use on patients for the irrigation of wounds and in pre-operative skin preparation.

Additionally, Microcyn has shown great promise in the areas of food sterilization and anti-bio-terrorism. Due to its non-toxic nature, disposal of Microcyn doesn't require costly environmental processes usually associated with more toxic competitive products.

The Conformité Européenne (“CE”) mark appears on products that meet safety standards that apply to all countries of the European Union (“EU”). It was created under the Single European Act and introduced to facilitate the free movement of goods within the EU. Obtaining the CE Mark proves to the authorities that the product meets essential requirements regarding safety.

Products bearing the CE mark, indicating that the manufacturer has conformed to all the requirements under EU legislation, can be traded freely throughout the EU territories (Europe) without further modification or testing.

“The successful audit and filing of the technical file are critical milestones as we move to introduce

Microcyn as a disinfectant in Europe this coming spring,” said CEO Hoji Alimi. “We’ve met every major project target on time and will continue to push forward to satisfy growing market demand for this truly disruptive technology.”

The CE approval will help in accelerating the company’s approvals and product launch plans for Microcyn as expansion continues in Latin America, Europe, Asia, Africa, the Middle East and the U.S.

### **About Oculus**

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative technologies that globally re-define the disinfectant and antiseptic markets. Oculus has developed the revolutionary Microcyn disinfectant and antiseptic with broad applications in such diverse markets as consumer, medical, dental, veterinarian, cosmetic, wound healing, food processing and anti-bio-terrorism. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V. Please visit us at [www.oculusis.com](http://www.oculusis.com).

**Release Corrected Jan. 11, 2004:** Original release posted on January 9, 2004, inadvertently indicated that the CE Mark Approval had been “obtained” when in fact, it has been “applied for.”

### **Forward-Looking Statements**

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.